Founded in 2017 by Dr. Martin Schiller of the University of Nevada, Heligenics Inc. was established to realize the promise of the functional genome and precision medicine.
"Heli" is derived from “hǣlan” an old English word that means “to heal” and “genics” which stands for genomics
Heligenics is a biotechnology company focused on functional genomics research and services. Our website showcases our expertise in understanding the effects of genetic variations on gene function, disease development, and drug response. We offer comprehensive genomic solutions to pharmaceutical and biotechnology companies, as well as healthcare providers, to advance personalized medicine and precision therapeutics.
Heligenics provides custom services in the drug development and molecular diagnostic space. This includes the construction of large variant libraries (consisting of every variant in a gene with 100s of copies) and the development of cell-based GigaAssays for testing these libraries. This approach assesses the functional consequence of every amino acid in a gene. Analogous to Genome-Wide Association Studies, this is both a hypothesis-independent and fully comprehensive approach. Such services help clients identify potential biologic and dual agonist drug targets, optimize drug candidates, design precision clinical trials, expand the market for a drug, and select among drugs for therapy. In the diagnostic space, the creation of our MEGA-Maps will resolve the diagnostic problem of variants of unknown significance.
What sets Heligenics apart is our innovative approaches and proprietary technologies, making them a valuable partner in genomics research. We are the first company in the pharmaceutical space to enable high-content screening for biologics, a previously well-established method for small molecule therapies. By leveraging their expertise, clients can gain a deeper understanding of the functional consequences of genetic variations and develop more effective treatments tailored to individual patients. Our commitment to advancing precision medicine has positioned us as a leader in the field of functional genomics.
To prevent disease and heal patients afflicted with illness through genomics.
Based on the GigaAssay technology developed at the University of Nevada Las Vegas in the Schiller Laboratory of Applied Bioinformatics, our GigaAssay is a massively parallel biological platform that can simultaneously measure how tens of thousands of genetic variants or other sequence variables affect a molecular function or a cell process. To date, there are no other established high-throughput assays that assess biological function.
The GigaAssay produces functional genomics data that can be licensed and used for prevention-based approaches, diagnostics, drug selection and discovery of new biologic drugs. Additionally, for developing new drug therapies or redesigning clinical trials for drugs that have failed a trial due to poor efficacy or safety. Heligenics products will transform the medical industry.